Fig. 6: Sensitivity of in vivo PDX models to LCL161.

Changes in tumour volumes and survival curve for PDX models after treatment with LCL161 and olaparib as single agents and in combination.

Changes in tumour volumes and survival curve for PDX models after treatment with LCL161 and olaparib as single agents and in combination.